Adrian Hill trained at Trinity College Dublin and Oxford is now Professor of Human Genetics and Director of the Jenner Institute at Oxford University. He leads research programmes in both the genetics of susceptibility to tropical infectious diseases and in vaccine development. His group identified heterologous prime-boost immunisation using non-replicating vectors as an exceptionally potent approach for inducing protective T cell responses in murine malaria and undertook the first clinical trials of this approach. In 2005 he was appointed Director of the Jenner Institute, a new initiative aimed at accelerating public sector vaccine development for a variety of infectious diseases. The Institute has a major interest in filling the gap between pre-clinical vaccine design and large-scale field efficacy trials. Over fifty clinical trials have been undertaken in recent years by Jenner Investigators who are developing new vaccines against malaria, HIV, tuberculosis, meningitis, pandemic influenza and hepatitis C. He currently also chairs the Clinical Biomanufacturing Facility and the Centre for Clinical Vaccinology and Tropical Medicine in Oxford. He is a Fellow of the UK Academy of Medical Sciences and a Wellcome Trust Senior Investigator. He has published over 400 research papers.